aTyr Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

aTyr Pharma wird ein Gewinn- und Umsatzwachstum von 66.9% bzw. 67.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 67.8% pro Jahr wachsen soll.

Wichtige Informationen

66.9%

Wachstumsrate der Gewinne

67.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	67.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Feb 03

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ATYR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	82	-6	N/A	N/A	5
12/31/2025	7	-59	N/A	N/A	5
12/31/2024	0	-64	N/A	N/A	5
3/31/2024	1	-54	-58	-55	N/A
12/31/2023	0	-50	-37	-33	N/A
9/30/2023	11	-43	-38	-33	N/A
6/30/2023	10	-45	-40	-35	N/A
3/31/2023	10	-45	-35	-32	N/A
12/31/2022	10	-45	-44	-42	N/A
9/30/2022	N/A	-46	-40	-40	N/A
6/30/2022	N/A	-41	-39	-39	N/A
3/31/2022	N/A	-39	-38	-37	N/A
12/31/2021	N/A	-34	-33	-33	N/A
9/30/2021	2	-30	-31	-30	N/A
6/30/2021	2	-29	-25	-24	N/A
3/31/2021	2	-25	-23	-23	N/A
12/31/2020	10	-16	-16	-15	N/A
9/30/2020	9	-17	-15	-15	N/A
6/30/2020	9	-16	-14	-14	N/A
3/31/2020	8	-16	-12	-12	N/A
12/31/2019	0	-24	-20	-20	N/A
9/30/2019	0	-24	-20	-20	N/A
6/30/2019	0	-25	-22	-22	N/A
3/31/2019	N/A	-30	-27	-27	N/A
12/31/2018	N/A	-35	-32	-31	N/A
9/30/2018	N/A	-40	-37	-37	N/A
6/30/2018	N/A	-44	-40	-39	N/A
3/31/2018	N/A	-45	-41	-39	N/A
12/31/2017	N/A	-48	N/A	-42	N/A
9/30/2017	N/A	-49	N/A	-44	N/A
6/30/2017	N/A	-52	N/A	-50	N/A
3/31/2017	N/A	-55	N/A	-54	N/A
12/31/2016	N/A	-58	N/A	-53	N/A
9/30/2016	N/A	-62	N/A	-51	N/A
6/30/2016	N/A	-59	N/A	-46	N/A
3/31/2016	N/A	-55	N/A	-43	N/A
12/31/2015	N/A	-48	N/A	-37	N/A
9/30/2015	N/A	-38	N/A	-33	N/A
6/30/2015	N/A	-33	N/A	-29	N/A
3/31/2015	N/A	-28	N/A	-23	N/A
12/31/2014	N/A	-25	N/A	-23	N/A
9/30/2014	N/A	-24	N/A	-21	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LIFE wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: LIFE wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: LIFE wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: LIFEDie Einnahmen des Unternehmens (70% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: LIFEDie Einnahmen des Unternehmens (70% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ATYR in 3 Jahren voraussichtlich hoch sein wird

aTyr Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 8.8% to US$24.60

Consensus revenue estimates decrease by 85%, EPS upgraded

Consensus revenue estimates fall by 70%

Forecast to breakeven in 2026

Consensus revenue estimates fall by 93%

Consensus EPS estimates upgraded to US$0.90 loss

Recent updates

Independent Chairman of the Board recently bought US$88k worth of stock

Price target increased by 8.8% to US$24.60

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Consensus revenue estimates decrease by 85%, EPS upgraded

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Consensus revenue estimates fall by 70%

New minor risk - Profitability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Consensus revenue estimates fall by 93%

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Consensus EPS estimates upgraded to US$0.90 loss

Price target increased by 17% to US$23.25

Consensus EPS estimates upgraded to US$1.03 loss

Independent Director recently bought US$450k worth of stock

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Consensus revenue estimates fall by 25%

Price target increased by 8.9% to US$22.00

Consensus revenue estimates decrease by 25%

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Consensus forecasts updated

Price target decreased to US$21.20

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

Consensus revenue estimates fall by 67%

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma gains with FDA Fast Track status for lead asset

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$17.33

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

Consensus revenue estimates fall by 33%

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Price target increased to US$19.25

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$199k worth of stock

Consensus forecasts updated

Price target increased to US$17.67

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

New 90-day high: US$8.06

Price target raised to US$13.33

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan